Bristol-Myers Squibb and Pharmasset have entered into a clinical collaboration agreement to evaluate BMS-790052, a NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset’s nucleotide polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV). The study will evaluate the potential to achieve sustained viral response 24 weeks post treatment with an oral, once-daily treatment regimen in patients across HCV genotypes. Specifically, the study will assess the sa...